PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2022 Results Earnings Conference Call August 8, 2022 8:00 AM ET
Company Participants
Gabrielle DeGravina - Investor Relations, CG Capital
Frank Bedu-Addo - Chief Executive Officer
Lauren Wood - Chief Medical Officer
Matthew Hill - Chief Financial Officer
Conference Call Participants
Louise Chen - Cantor Fitzgerald
James Molloy - Alliance Global Partners
Leland Gershell - Oppenheimer & Co.
Joseph Pantginis - H. C. Wainwright & Co.
Robert LeBoyer - Noble Capital Markets
Operator
Greetings. Welcome to PDS Biotech Second Quarter 2022 Earnings Call and Webcast. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note that this conference is being recorded.
At this time, I'll turn the conference over to Gabby DeGravina with Investor Relations. Gabby, you may now begin.
Gabrielle DeGravina
Good morning. And welcome to PDS Biotechnology's second quarter 2022 earnings conference call and audio webcast. With me today from the company are Dr. Frank Bedu-Addo, Chief Executive Officer, Dr. Lauren B. Wood, Chief Medical Officer, and Matt Hill, Chief Financial Officer.
Earlier this morning, PDS Biotech issued a press release announcing financial results for the quarter ended June 30, 2022. We encourage everyone to read the press release as well as PDS Biotech's report on Form 10-Q, which will be filed with the SEC shortly. The company's press release is available on the PDS website at pdsbiotech.com.
In addition, this conference call is being webcast and will be archived on the company website for future reference.
Before we begin, we need to remind everyone that, on today's call, the company will be making forward-looking statements regarding regulatory and product candidate development plans, as well as research activity. Certain information in this presentation may include forward-looking statements, including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended in Section 27A of the United States Securities Act of 1933 as amended, concerning PDS Biotechnology Corporation and other matters.
These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations, or financial condition or otherwise based on current beliefs of the company's management, as well as assumptions made by, and information currently available to, management.
These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these can be found in PDS Biotech's most recent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. Except to the extent which is required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included today to reflect subsequent events or circumstances.